Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-nectin-4 parental antibody-drug conjugate
- Development stage
- Preclinical
- Lead developer
- Biocytogen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The anti-nectin-4 parental antibody-drug conjugate is a monovalent ADC targeting Nectin-4 (Poliovirus receptor-related protein 4), developed by Biocytogen as a foundational component and benchmark for their bispecific ADC program, BCG039 (a Nectin-4 x TROP2 bispecific ADC). The antibody component is a fully human monoclonal antibody generated using Biocytogen's RenLite transgenic mouse platform. In preclinical studies, this parental ADC has been conjugated to various payloads, including the microtubule inhibitor monomethyl auristatin E (MMAE) via a valine-citrulline (vc) linker and Biocytogen's proprietary BLD1102 linker-payload, which features a novel topoisomerase 1 (TOP1) inhibitor. It is used in comparative assays to demonstrate the superior internalization and anti-tumor efficacy of the bispecific format in models of urothelial carcinoma and other solid tumors.
- Other names
- monovalent parental anti-nectin-4 ADCnectin-4 monovalent parental ADCnectin4 monovalent parental ADCnectin 4 monovalent parental ADC
02
Targets
MicrotubulePVRL4 (Nectin cell adhesion molecule 4)
Beyond the preview
Go deeper on anti-nectin-4 parental antibody-drug conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-nectin-4 parental antibody-drug conjugate.